Bailard Inc. Sells 9,850 Shares of DexCom, Inc. (NASDAQ:DXCM)

Bailard Inc. decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 15.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 55,668 shares of the medical device company's stock after selling 9,850 shares during the quarter. Bailard Inc.'s holdings in DexCom were worth $6,908,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Sands Capital Management LLC boosted its stake in shares of DexCom by 4.3% during the third quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company's stock worth $1,274,541,000 after buying an additional 557,543 shares during the period. Blair William & Co. IL grew its position in DexCom by 1.7% in the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company's stock valued at $420,517,000 after buying an additional 73,654 shares during the last quarter. Northern Trust Corp increased its stake in DexCom by 2.4% in the 3rd quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company's stock valued at $363,545,000 after buying an additional 91,249 shares during the period. Charles Schwab Investment Management Inc. raised its position in DexCom by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,160,961 shares of the medical device company's stock worth $201,618,000 after buying an additional 28,621 shares during the last quarter. Finally, Winslow Capital Management LLC acquired a new stake in shares of DexCom in the 3rd quarter worth $173,120,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Trading Up 0.1 %

Shares of DXCM traded up $0.14 during mid-day trading on Thursday, hitting $138.01. The company had a trading volume of 4,198,985 shares, compared to its average volume of 2,977,786. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The business's 50-day simple moving average is $130.98 and its 200-day simple moving average is $118.02. The stock has a market cap of $54.66 billion, a PE ratio of 105.35, a P/E/G ratio of 2.30 and a beta of 1.20. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.07. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. DexCom's revenue for the quarter was up 26.9% on a year-over-year basis. During the same quarter last year, the business earned $0.34 EPS. Sell-side analysts forecast that DexCom, Inc. will post 1.76 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 20,321 shares of the firm's stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now directly owns 80,441 shares in the company, valued at approximately $10,747,722.01. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, EVP Sadie Stern sold 20,321 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the sale, the executive vice president now owns 80,441 shares of the company's stock, valued at $10,747,722.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the firm's stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 189,375 shares of company stock valued at $25,530,859. Company insiders own 0.41% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on DXCM. Royal Bank of Canada assumed coverage on shares of DexCom in a report on Tuesday, March 12th. They set an "outperform" rating and a $165.00 price target for the company. StockNews.com cut DexCom from a "buy" rating to a "hold" rating in a research report on Tuesday. Raymond James boosted their target price on shares of DexCom from $147.00 to $151.00 and gave the stock a "strong-buy" rating in a research report on Tuesday, January 23rd. UBS Group increased their price target on shares of DexCom from $153.00 to $163.00 and gave the company a "buy" rating in a report on Wednesday, April 10th. Finally, Citigroup boosted their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, DexCom currently has an average rating of "Moderate Buy" and an average price target of $141.40.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.